Publication:
TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

dc.contributor.coauthorLabiano, I.
dc.contributor.coauthorAgirre-Lizaso, A.
dc.contributor.coauthorOlaizola, P.
dc.contributor.coauthorEchebarria, A.
dc.contributor.coauthorHuici-Izagirre, M.
dc.contributor.coauthorOlaizola, I.
dc.contributor.coauthorEsparza Baquer, A.
dc.contributor.coauthorSharif, O.
dc.contributor.coauthorHijona, E.
dc.contributor.coauthorMilkiewicz, P.
dc.contributor.coauthorMilkiewicz, M.
dc.contributor.coauthorGonzalez-Romero, F.
dc.contributor.coauthorAspichueta, P.
dc.contributor.coauthorMonte, M.J.
dc.contributor.coauthorMarin, J.J.G.
dc.contributor.coauthorVucur, M.
dc.contributor.coauthorLuedde, T.
dc.contributor.coauthorMarzioni, M.
dc.contributor.coauthorBujanda, L.
dc.contributor.coauthorRodrigues, P.M.
dc.contributor.coauthorBanales, J.M.
dc.contributor.coauthorPerugorria, M.J.
dc.contributor.kuauthorMann, Derek Austin
dc.contributor.kuprofileOther
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.date.accessioned2024-11-09T13:07:04Z
dc.date.issued2022
dc.description.abstractBackgroundand aims: inflammation, particularly that mediated by bacterial components translocating from the gut to the liver and binding to toll-like receptors (TLRs), is central to cholestatic liver injury. The triggering receptor expressed on myeloid cells-2 (TREM-2) inhibits TLR-mediated signaling and exerts a protective role in hepatocellular injury and carcinogenesis. This study aims to evaluate the role of TREM-2 in cholestasis.Methods: TREM-2 expression was analyzed in the livers of pa-tients with primary biliary cholangitis (PBC) or primary scle-rosing cholangitis (PSC), and in mouse models of cholestasis. Wild-type (WT) and Trem-2 deficient (Trem-2-/-) mice were subjected to experimental cholestasis and gut sterilization. Pri-mary cultured Kupffer cells were incubated with lipopolysac-charide and/or ursodeoxycholic acid (UDCA) and inflammatory responses were analyzed.Results: TREM-2 expression was upregulated in the livers of patients with PBC or PSC, and in murine models of cholestasis. Compared to WT, the response to bile duct ligation (BDL)-induced obstructive cholestasis or alpha-naphtylisothiocyanate (ANIT)-induced cholestasis was exacerbated in Trem-2-/-mice. This was characterized by enhanced necroptotic cell death, in-flammatory responses and biliary expansion. Antibiotic treat-ment partially abrogated the effects observed in Trem-2-/-mice after BDL. Experimental overexpression of TREM-2 in the liver of WT mice downregulated ANIT-induced IL-33 expression and neutrophil recruitment. UDCA regulated Trem-1 and Trem-2 expression in primary cultured mouse Kupffer cells and damp-ened inflammatory gene transcription via a TREM-2-dependent mechanism.Conclusions: TREM-2 acts as a negative regulator of inflamma-tion during cholestasis, representing a novel potential thera-peutic target.Lay summary: Cholestasis (the reduction or cessation of bile flow) causes liver injury. This injury is exacerbated when gut-derived bacterial components interact with receptors (spe-cifically Toll-like receptors or TLRs) on liver-resident immune cells, promoting inflammation. Herein, we show that the anti-inflammatory receptor TREM-2 dampens TLR-mediated signaling and hence protects against cholestasis-induced liver injury. Thus, TREM-2 could be a potential therapeutic target in cholestasis.
dc.description.fulltextYES
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue4
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuEU
dc.description.sponsorshipEuropean Union (EU)
dc.description.sponsorshipHorizon 2020
dc.description.sponsorshipEuropean Research Council (ERC)
dc.description.sponsorshipSpanish Carlos III Health Institute (ISCIII)
dc.description.sponsorshipFondo Europeo de Desarrollo Regional (FEDER)
dc.description.sponsorshipDiputaciĆ³n Foral de Gipuzkoa
dc.description.sponsorshipDepartment of Health of the Basque Country
dc.description.sponsorshipEuskadi RIS3
dc.description.sponsorshipDepartment of Industry of the Basque Country
dc.description.sponsorshipJunta de Castilla y Leon
dc.description.sponsorshipLa Caixa Scientific Foundation
dc.description.sponsorshipCentro Internacional sobre el Envejecimiento
dc.description.sponsorshipFundaciĆ³ Marato TV3
dc.description.sponsorshipAustrian Science Fund
dc.description.sponsorshipGerman Research Foundation (DFG)
dc.description.sponsorshipGerman Ministry of Health (BMG)
dc.description.sponsorshipDEEP LIVER
dc.description.sponsorshipUniversitĆ  Politecnica delle Marche
dc.description.sponsorshipCRUK
dc.description.sponsorshipMRC
dc.description.sponsorshipSpanish Ministry of Economy and Competitiveness
dc.description.sponsorshipMINECO
dc.description.sponsorshipā€œRamĆ³n y Cajalā€ Programme
dc.description.sponsorshipMinistry of Universities
dc.description.sponsorshipUniversity of the Basque Country
dc.description.sponsorshipInstituto de Salud Carlos III (CIBERehd)
dc.description.sponsorshipFundaciĆ³n CientĆ­fica de la AsociaciĆ³n EspaƱola Contra el CĆ”ncer (AECC Scientific Foundation)
dc.description.sponsorshipSFB-CRC 1382-Project A01
dc.description.versionPublisher version
dc.description.volume77
dc.formatpdf
dc.identifier.doi10.1016/j.jhep.2022.05.044
dc.identifier.eissn1600-0641
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR03812
dc.identifier.issn0168-8278
dc.identifier.linkhttps://doi.org/10.1016/j.jhep.2022.05.044
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85136756265
dc.identifier.urihttps://hdl.handle.net/20.500.14288/2546
dc.identifier.wos868321600014
dc.keywordsCholangiopathies
dc.keywordsInflammation
dc.keywordsInnate immunity
dc.keywordsLiver resident macrophages
dc.keywordsTREM receptors
dc.keywordsUrsodeoxycholic acid
dc.languageEnglish
dc.publisherElsevier
dc.relation.grantno771083
dc.relation.grantnoFIS PI18/ 01075
dc.relation.grantnoPI21/00922
dc.relation.grantnoCPII19/00008
dc.relation.grantnoFIS PI14/00399
dc.relation.grantnoPI17/00022
dc.relation.grantnoPI20/00186
dc.relation.grantnoFIS PI16/00598
dc.relation.grantnoPI19/00819
dc.relation.grantnoCD19/00254
dc.relation.grantnoDFG18/114
dc.relation.grantno2019111024
dc.relation.grantno2015111100
dc.relation.grantno202111102
dc.relation.grantno2019222054
dc.relation.grantno2020333010
dc.relation.grantno2021333003
dc.relation.grantnoKK-2020/00008
dc.relation.grantnoSA063P17
dc.relation.grantnoHR17- 00601
dc.relation.grantnoOLD-HEPAMARKER
dc.relation.grantno0348_CIE_6_E
dc.relation.grantno201916-31
dc.relation.grantnoFWF-P35168
dc.relation.grantno279874820
dc.relation.grantnoLU 1360/3-2
dc.relation.grantnoLU 1360/4-(1461704932)
dc.relation.grantno2520DAT111
dc.relation.grantnoPSA2017_UNIVPM
dc.relation.grantnoC18342/A23390
dc.relation.grantnoMR/K0019494/1
dc.relation.grantnoMR/R023026/1
dc.relation.grantnoRYC-2015-17755
dc.relation.grantnoFPU 19/03327
dc.relation.grantnoPIF2014/11
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10669
dc.sourceJournal of Hepatology
dc.subjectGastroenterology and hepatology
dc.titleTREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorMann, Derek Austin

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10669.pdf
Size:
3.84 MB
Format:
Adobe Portable Document Format